OBJECTIVES: The aim of this study was to describe the impact of frailty in patients undergoing percutaneous mitral valve repair (PMVR). BACKGROUND: Frailty is common in elderly patients and those with comorbidities and is associated with adverse prognosis. METHODS: Frailty according to the Fried criteria was assessed in consecutive patients admitted for PMVR. Associations of frailty with 6-week (device success, changes in 6-min walking distance and Minnesota Living With Heart Failure Questionnaire and Short Form 36 physical and mental component scores, and improvement ≥1 New York Heart Association functional class) and long-term outcomes during a median follow-up period of 429 days were examined. RESULTS: Of 213 patients admitted for PMVR (median age 78 years; age range 50 to 95 years; 57.3% men), 45.5% were classified as frail. Compared with nonfrail patients, frail patients had a similar device success rate (81.4% vs. 84.5%; p = 0.56) and improvement in 6-min walking distance, New York Heart Association functional class, and Short Form-36 scores but a more pronounced improvement in Minnesota Living With Heart Failure Questionnaire score (mean change -15.9 vs. -11.2 points; p = 0.002). Mortality at 6 weeks was significantly higher in frail (8.3%) compared with nonfrail (1.7%) patients (p = 0.03). Hazards of death (hazard ratio: 3.06; 95% confidence interval: 1.54 to 6.07; p = 0.001) and death or heart failure decompensation (hazard ratio: 2.03; 95% confidence interval: 1.22 to 3.39; p = 0.007) were significantly increased in frail patients during long-term follow-up, which did not change relevantly after adjustment for European System for Cardiac Operative Risk Evaluation score and N-terminal pro-brain natriuretic peptide level. CONCLUSIONS: PMVR can be performed with equal efficacy and is associated with at least similar short-term functional improvement in frail patients. These results support the continued use of PMVR in frail elderly patients with the goal of palliation of heart failure symptoms and improvement in quality of life.
OBJECTIVES: The aim of this study was to describe the impact of frailty in patients undergoing percutaneous mitral valve repair (PMVR). BACKGROUND: Frailty is common in elderly patients and those with comorbidities and is associated with adverse prognosis. METHODS: Frailty according to the Fried criteria was assessed in consecutive patients admitted for PMVR. Associations of frailty with 6-week (device success, changes in 6-min walking distance and Minnesota Living With Heart Failure Questionnaire and Short Form 36 physical and mental component scores, and improvement ≥1 New York Heart Association functional class) and long-term outcomes during a median follow-up period of 429 days were examined. RESULTS: Of 213 patients admitted for PMVR (median age 78 years; age range 50 to 95 years; 57.3% men), 45.5% were classified as frail. Compared with nonfrail patients, frail patients had a similar device success rate (81.4% vs. 84.5%; p = 0.56) and improvement in 6-min walking distance, New York Heart Association functional class, and Short Form-36 scores but a more pronounced improvement in Minnesota Living With Heart Failure Questionnaire score (mean change -15.9 vs. -11.2 points; p = 0.002). Mortality at 6 weeks was significantly higher in frail (8.3%) compared with nonfrail (1.7%) patients (p = 0.03). Hazards of death (hazard ratio: 3.06; 95% confidence interval: 1.54 to 6.07; p = 0.001) and death or heart failure decompensation (hazard ratio: 2.03; 95% confidence interval: 1.22 to 3.39; p = 0.007) were significantly increased in frail patients during long-term follow-up, which did not change relevantly after adjustment for European System for Cardiac Operative Risk Evaluation score and N-terminal pro-brain natriuretic peptide level. CONCLUSIONS: PMVR can be performed with equal efficacy and is associated with at least similar short-term functional improvement in frail patients. These results support the continued use of PMVR in frail elderly patients with the goal of palliation of heart failure symptoms and improvement in quality of life.
Authors: Suzanne V Arnold; Khaja M Chinnakondepalli; John A Spertus; Elizabeth A Magnuson; Suzanne J Baron; Saibal Kar; D Scott Lim; Jacob M Mishell; William T Abraham; JoAnn A Lindenfeld; Michael J Mack; Gregg W Stone; David J Cohen Journal: J Am Coll Cardiol Date: 2019-03-17 Impact factor: 24.094
Authors: Harun Kundi; Jeffrey J Popma; Matthew R Reynolds; Jordan B Strom; Duane S Pinto; Linda R Valsdottir; Changyu Shen; Eunhee Choi; Robert W Yeh Journal: Eur Heart J Date: 2019-07-14 Impact factor: 29.983
Authors: Suzanne V Arnold; Zhuokai Li; Sreekanth Vemulapalli; Suzanne J Baron; Michael J Mack; Andrzej S Kosinski; Matthew R Reynolds; James B Hermiller; John S Rumsfeld; David J Cohen Journal: JAMA Cardiol Date: 2018-12-01 Impact factor: 14.676
Authors: Harun Kundi; Jeffrey J Popma; Linda R Valsdottir; Changyu Shen; Kamil F Faridi; Duane S Pinto; Robert W Yeh Journal: Can J Cardiol Date: 2018-10-13 Impact factor: 5.223
Authors: Naila Ijaz; Brian Buta; Qian-Li Xue; Denise T Mohess; Archana Bushan; Henry Tran; Wayne Batchelor; Christopher R deFilippi; Jeremy D Walston; Karen Bandeen-Roche; Daniel E Forman; Jon R Resar; Christopher M O'Connor; Gary Gerstenblith; Abdulla A Damluji Journal: J Am Coll Cardiol Date: 2022-02-08 Impact factor: 24.094
Authors: Pablo Solla-Suárez; Pablo Avanzas; Isaac Pascual; Manuel Bermúdez-Menéndez De La Granda; Marcel Almendarez; Jose M Arche-Coto; Daniel Hernández-Vaquero; Rebeca Lorca; Eva López-Álvarez; Rut Álvarez-Velasco; Carmen Moreno-Planillo; César Morís de la Tassa; José Gutiérrez-Rodríguez Journal: J Clin Med Date: 2021-05-27 Impact factor: 4.241